M. Patnaik

Publications633
h-index48
Citations8,810
Highly Influential Citations369
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • A. Tefferi
  • 1,638 Publications • 83,872 Citations
  • H. Kantarjian
  • 4,842 Publications • 223,916 Citations
  • A. Pardanani
  • 668 Publications • 30,767 Citations
  • N. Gangat
  • 462 Publications • 10,565 Citations
  • Publications
  • Influence
Anthracycline dose intensification in acute myeloid leukemia.
View on PubMed
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors.
TLDR
The current study validates the prognostic relevance of the WHO subclassification of SM and provides additional information of value in terms of both risk stratification and interpretation of clinical presentation and laboratory results.
View on PubMed
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
TLDR
It is shown that GM-CSF neutralization with lenzilumab does not inhibit CART19 cell function in vitro or in vivo, and a novel approach to abrogate NI and CRS through GM- CSF neutralized, which may potentially enhance CAR-T cell function.
View on PubMed
Eosinophilia: secondary, clonal and idiopathic
TLDR
The current communication features a comprehensive clinical summary of both secondary and primary eosinophilic disorders with emphasis on recent developments in molecular pathogenesis and treatment.
View on Wiley
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.
TLDR
Imetelstat was found to be active in patients with myelofibrosis but also had the potential to cause clinically significant myelosuppression.
View on PubMed
SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival.
TLDR
SRSF2 mutations are relatively common in PMF, cluster with IDH mutations, and are independently predictive of poor outcome, including shortened overall and leukemia-free survival.
View on PubMed
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.
TLDR
Tyrosine kinase inhibitor (TKI) therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML (CP-CML).
View on PubMed
Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance
TLDR
It is concluded that SRSF2 is the most frequently mutated spliceosome gene in CMML but neither it nor SF3B1 or U2AF35 mutations are prognostically relevant.
View on Wiley
Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.
TLDR
Three specific mutations that might bear pathogenetic relevance for leukemic transformation in MPN are pointed to and an adverse survival effect of RUNX1 mutations is suggested, which is associated with shorter survival duration.
View on PubMed
Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia
TLDR
Using age >67 years, hemoglobin <10 gm/dL and the presence of TET2 mutations to create a hazard ratio weighted prognostic model, stratifying patients into two risk categories, low (0‐1 risk factor) and high (≥2 risk factors), with median OS of 18 and 7 months, respectively.
View on Wiley
...
...